Using Quantitative Bias Analysis to Adjust for Misclassification of <scp>COVID</scp> ‐19 Outcomes: An Applied Example of Inhaled Corticosteroids and <scp>COVID</scp> ‐19 Outcomes
We observed increased risks of COVID-19 hospitalisation and death among ICS users compared to LABA/LAMA users. Outcome misclassification was unlikely to change the conclusions of the study, but confounding by indication remains a concern.
Authors
- Christopher T. Rentsch (ORCID: https://orcid.org/0000-0002-1408-7907)
- Jacob N. Hunnicutt (ORCID: https://orcid.org/0000-0003-2768-0272)
- Jennifer Kathleen Quint (ORCID: https://orcid.org/0000-0003-0149-4869)
- Anna Schultze
- Ian Douglas (ORCID: https://orcid.org/0000-0002-8970-1406)
- Marleen Bokern (ORCID: https://orcid.org/0000-0002-1481-3331)
Institutions
- London School of Hygiene & Tropical Medicine (GB)
- Lung Institute (US)
- Boehringer Ingelheim (United States) (US)
- Imperial College London (GB)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/pds.70086
- Citations
- 6
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 8.38